NCT07675031Available不适用
Managed Access Program of Venglustat in Pediatric and Adult Patients With Type 3 Gaucher Disease (GD3).
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
- 发起方
- Sanofi
研究概览
简要总结
The objective of this program is to provide early access to venglustat for certain patients with Gaucher disease type 3 in response to unsolicited requests from healthcare providers. No approved therapies for the CNS manifestations of the disease are currently available. The program will provide access to venglustat prior to registration and the availability of commercial product (including reimbursement where applicable) in the country of the patient.
详细描述
The program provides access to venglustat, an investigational therapy.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 12 years of age
- •Clinical diagnosis of GD3 with at least 1 CNS manifestation
- •Body weight ≥15 kg
- •On a stable ERT dose for at least 6 months
- •Clinically stable with respect to hematologic manifestations
- •Clinically stable with respect to spleen and liver volume
- •If the patient has a history of seizures, they must be well controlled without use of medications that are strong/moderate inducers or strong/moderate inhibitors of CYP3A
- •Documented negative pregnancy test
- •Contraceptive use consistent with local regulations.
排除标准
- •Inability to safely swallow (or chew and swallow) a venglustat tablet
- •Use of any investigational drugs within the last 30 days or 5 half-lives or gene therapy at any time
- •Current use of any unapproved therapy for GD
- •Pregnant or breastfeeding females
- •Drug contraindications
- •History of major organ transplant (eg, bone marrow or liver)
- •History of drug and/or alcohol abuse within the last year
- •Patients with severe depression and/or a history of a major affective disorder in the past year
- •Patients with suicidal ideation or behavior prior to study.
- •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
研究者
相似试验
招募中
3 期
Study to evaluate the efficacy and safety of venglustat in adult and pediatric patients with Gaucher disease Type 32024-514381-39-00Sanofi-Aventis Recherche & Developpement15
招募中
2 期
Guanabenz in VWM2023-503320-89-00Amsterdam UMC40
Available
不适用
Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid TumorsUrinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional CellNCT07675057Eli Lilly and Company
Unknown
不适用
儿童患者万古霉素使用的真实世界研究感染性疾病ChiCTR19000223082019 年中国药学会科技开发中心项目（CMEI2019KPYJ(JZYY)00203）200
招募中
3 期
A Study of Efficacy, Safety, and Pharmacokinetics of Guselkumab in the Treatment of Chronic Plaque Psoriasis in Pediatric Participants2023-503378-19-00Janssen - Cilag International97